Gamma interferon data

Researchers presented positive long-term data from an open-label Phase II study in patients with severe atopic dermatitis who were treated with gamma interferon. As described at the Clinical Dermatology 2000 meeting in Vancouver, patients had first completed a 12 week, double-blind, placebo-controlled trial. A total of 24 patients completed one year of therapy and 16 patients completed two years. Dosing was 50 µ/m2/day or every other day, subcutaneously, depending on extent of disease.

Overall response, body surface area involvement, and clinical severity scores for erythema (redness of skin), edema (swelling), pruritis (itching), excoriations (scratch marks), scaling and lichenification (accentuation of skin markings), were monitored at quarterly visits. ...